Greenberg Traurig, LLP shareholders Lori G. Cohen and Mathew Rosengart have been named to Forbes' 2026 America's Top Lawyers list.

Cohen, vice chair of the firm and co-chair of its Global Litigation Practice and Trial Practice Group, was recognized for the second consecutive year. Rosengart, co-chair of the National Media & Entertainment Litigation Practice, was recognized for the third consecutive year, beginning with Forbes' inaugural 2024 list.

Practice Focus

Cohen focuses on complex products liability, pharmaceutical, medical device, and health care litigation. She serves as national, regional, and trial counsel for major manufacturers in class actions and multidistrict litigation nationwide. Cohen built the firm's Pharmaceutical, Medical Device & Health Care Litigation Practice, which includes more than 100 attorneys across more than 30 offices. She holds a record of 58 defense verdicts.

Rosengart handles high-stakes media, entertainment, commercial, and white collar matters for prominent individuals and companies. A former federal prosecutor and Justice Department trial attorney, he is ranked by Chambers USA. He was named Benchmark Litigation's Entertainment Litigator of the Year in both 2024 and 2025.

Firm Overview

Greenberg Traurig has approximately 3,200 lawyers across 51 locations in the United States, Europe, the Middle East, Latin America, and Asia. The firm is consistently ranked among the top firms on the Am Law Global 100, NLJ 500, and Law360 400 lists.

Global law firm Greenberg Traurig, LLP has appointed Kunyong Yang as a shareholder in its San Diego office, strengthening its Intellectual Property & Technology Practice.

Yang joins the Patents and Innovation Strategies Group, bringing experience as a former medicinal chemist and patent attorney focused on pharmaceutical and biotechnology innovations.

Strategic Expansion in Life Sciences

Yang advises emerging biotechnology companies, clinical-stage drug developers, and multinational pharmaceutical firms on global patent portfolios, intellectual property due diligence, licensing transactions, and lifecycle management strategies.

His background includes nearly a decade as a scientist before entering the legal profession. This scientific expertise allows him to address complex areas such as small molecule therapeutics, antibody-drug conjugates, radiopharmaceuticals, mRNA, siRNA, and other cutting-edge technologies.

Leadership Perspective

Mark R. Galis, Global Intellectual Property & Technology Practice Co-Chair, highlighted the value of Yang’s dual background.

"Kunyong’s combination of scientific experience, deep pharmaceutical patent knowledge, and international perspective makes him an outstanding addition to our platform," Galis said. "As innovation continues to accelerate across life sciences, biotechnology, and artificial-intelligence-driven drug discovery, Kunyong enhances our ability to help clients protect and maximize the value of their most important innovations worldwide."

Client Representation and Expertise

Yang is recognized for helping innovators develop and defend strategic patent portfolios that support business growth, investment, licensing, and commercialization. His experience spans the innovation lifecycle, from early-stage discovery through regulatory exclusivity and late-stage portfolio management.

He also possesses experience in Hatch-Waxman litigation and post-grant proceedings before the U.S. Patent and Trademark Office. Additionally, his fluency in Mandarin Chinese supports clients on cross-border IP matters involving the United States and Asia.

Notable representations include:

• Helping establish global patent portfolios for Nuvalent, Inc., covering precision medicines targeting specific kinases in oncology therapies.
• Advising Allorion Therapeutics on patent matters and IP due diligence for global licensing transactions involving clinical-stage and preclinical cancer therapies.
• Developing patent portfolios for innovative oncology, fibrosis, and metabolic disease therapies.

Professional Background

Yang previously worked with Greenberg Traurig patent and life science shareholders Christopher C. Bolten, Jeffery C. Giering, Ph.D., and Micheal L. Hebert, Ph.D. at Jones Day.

"Having worked as a scientist and inventor before entering the legal profession, I understand both the challenges and the significance of bringing new therapies to patients," Yang said. "The most valuable outcomes of years of research often reside in a company’s intellectual property. This firm’s entrepreneurial culture, innovative approach, and strong reputation in technology and life sciences make it an exciting platform to help clients protect the next generation of scientific breakthroughs."

Yang earned his J.D., magna cum laude, from the University of San Diego School of Law. He holds a master’s degree in organic chemistry from Michigan Technological University and a bachelor’s degree from Nanjing University. He is admitted to practice in California and before the U.S. Patent and Trademark Office.

About Greenberg Traurig

Greenberg Traurig, LLP has approximately 3,200 lawyers across 51 locations in the United States, Europe, the Middle East, Latin America, and Asia. The firm is recognized as a 2025 BTI "Best of the Best Recommended Law Firm" by general counsel for trust and relationship management. It is consistently ranked among the top firms on the Am Law Global 100, NLJ 500, and Law360 400.